Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Pramipexole (compound)

Name: pramipexol
PubChem Compound ID: 119569
Molecular formula: C10H19Cl2N3S
Molecular weight: 284.249 g/mol
SND-919CL2Y; 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, dihydrochloride, (S)-; PNU-98528E; Sifrol; BI-Sifrol; Mirapexin; SND-919; U-98528E; 104632-25-9; SND 19.
show more »
Name: pramipexol
Name (isomeric): DB00413
Drug Type: small molecule
Pramipexole hydrochloride; Pramipexol [Spanish]; Pramipexole 2HCl Monohydrate; Pramipexol; Pramipexolum [Latin]; Furfuryl Acetate
Brand: Mirapex
Category: Antidyskinetics, Antioxidants, Free Radical Scavengers, Antiparkinson Agents, Dopamine Agonists
CAS number: 104632-26-0
Indication: For the treatment of signs and symptoms of idiopathic Parkinson's disease
Pramipexole is a nonergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The relevance of D3 receptor binding in Parkinson's disease is unknown. The precise mechanism of action of Pramipexole...
show more »
Mechanism of Action: The precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum.
Absorption: Rapid. Absolute bioavailability is greater than 90%, indicating that pramipexole is well absorbed and undergoes little presystemic metabolism. Food does not affect the extent of absorption.
Protein binding: About 15% bound to plasma proteins.
Biotransformation: No metabolites have been identified in plasma or urine.
Route of elimination: Urinary excretion is the major route of pramipexole elimination, with 90% of a pramipexole dose recovered in urine, almost all as unchanged drug. Nonrenal routes may contribute to a small extent to pramipexole elimination, although no metabolites have been identified in plasma or urine.
Half Life: 8 hours
Clearance: renal cl=400 mL/min
Affected organisms: Humans and other mammals
Food interaction:
Take without regard to meals, however if nausea is a problem, taking the product with food may reduce its incidence.
Drug interaction:
PaliperidoneThe atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, pramipexole. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary.
ZuclopenthixolAntagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and pramipexole, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.
CimetidineCimetidine may increase the effect and toxicity of pramipexole.
TriprolidineThe CNS depressants, Triprolidine and Pramipexole, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
ZiprasidoneThe atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, pramipexole. Consider alternate therapy or monitor for worsening of movement disorder.
show more »